BE678807A - - Google Patents

Info

Publication number
BE678807A
BE678807A BE678807DA BE678807A BE 678807 A BE678807 A BE 678807A BE 678807D A BE678807D A BE 678807DA BE 678807 A BE678807 A BE 678807A
Authority
BE
Belgium
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26260578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE678807(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB34989/62A external-priority patent/GB1013907A/en
Application filed filed Critical
Publication of BE678807A publication Critical patent/BE678807A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/64—Preparation of O-metal compounds with O-metal group bound to a carbon atom belonging to a six-membered aromatic ring
    • C07C37/66—Preparation of O-metal compounds with O-metal group bound to a carbon atom belonging to a six-membered aromatic ring by conversion of hydroxy groups to O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
    • C07C37/055—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE678807D 1962-09-13 1966-03-31 BE678807A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB34989/62A GB1013907A (en) 1962-09-13 1962-09-13 Alkene derivatives
GB30755/65A GB1064629A (en) 1962-09-13 1965-07-20 Alkene derivatives

Publications (1)

Publication Number Publication Date
BE678807A true BE678807A (cg-RX-API-DMAC7.html) 1966-09-30

Family

ID=26260578

Family Applications (2)

Application Number Title Priority Date Filing Date
BE637389D BE637389A (cg-RX-API-DMAC7.html) 1962-09-13
BE678807D BE678807A (cg-RX-API-DMAC7.html) 1962-09-13 1966-03-31

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BE637389D BE637389A (cg-RX-API-DMAC7.html) 1962-09-13

Country Status (8)

Country Link
US (1) US4536516A (cg-RX-API-DMAC7.html)
BE (2) BE678807A (cg-RX-API-DMAC7.html)
BR (2) BR6352734D0 (cg-RX-API-DMAC7.html)
CH (3) CH441286A (cg-RX-API-DMAC7.html)
DE (1) DE1568834A1 (cg-RX-API-DMAC7.html)
DK (3) DK118655B (cg-RX-API-DMAC7.html)
FR (1) FR1502607A (cg-RX-API-DMAC7.html)
GB (1) GB1064629A (cg-RX-API-DMAC7.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2401132A1 (fr) * 1977-08-22 1979-03-23 Ici Ltd Nouveaux derives de triphenylbutene-1, leur procede de production et composition pharmaceutique les contenant
FR2463121A1 (fr) * 1979-08-15 1981-02-20 Egyt Gyogyszervegyeszeti Gyar Derives du 1,1,2-triphenylpropane et du 1,1,2-triphenylpropene, procede de preparation de ces derives et compositions pharmaceutiques contenant ces nouveaux composes
EP0659421A1 (en) * 1993-12-21 1995-06-28 Eli Lilly And Company 2-Phenyl-3-azoylbenzothiophenes for treating menstrual symptoms
EP0659420A1 (en) * 1993-12-21 1995-06-28 Eli Lilly And Company 2-Phenyl-3-azoylbenzothiophenes for treating sexual precocity
EP0659415A3 (en) * 1993-12-21 1995-10-11 Lilly Co Eli Inhibition of vasomotor symptoms and treatment of psychological complaints related to post-menopausal syndrome.
EP0659413A3 (en) * 1993-12-21 1995-10-11 Lilly Co Eli Inhibiting CNS problems in postmenopausal women.

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (cg-RX-API-DMAC7.html) * 1962-09-13
GB1560274A (en) * 1977-02-28 1980-02-06 Ici Ltd Phenylbut 1-ene derivatives having antiostrogenicactivity
EP0002097B1 (en) * 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
EP0127128B1 (en) * 1983-05-24 1987-02-25 Bristol-Myers Company Process for the conversion of the e isomer of 1,2-diphenyl-1-(4-(2-dimethylaminoethoxy)-phenyl)-1-butene to tamoxifen hcl
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4806685A (en) * 1985-08-05 1989-02-21 Gyogyszerkutato Inteezet/Pharmaceutical Research Institute 1,1,2-triphenylpropane and -propene derivatives
GB8604528D0 (en) * 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
CA1289570C (en) * 1986-06-16 1991-09-24 Tetsuji Asao 1,1,2-triaryl-1-alkene derivatives
ATE80152T1 (de) * 1987-04-21 1992-09-15 Heumann Pharma Gmbh & Co Stabile loesungsmitteladdukte von z-1-(p-betadimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl) 2-phenylbut-1-en.
DE3736682A1 (de) * 1987-10-29 1989-05-11 Klinge Co Chem Pharm Fab Verfahren zur herstellung von trans-1,1,2-triphenyl-but-1-en-derivaten
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5204337A (en) * 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
US5364847A (en) * 1989-03-10 1994-11-15 Endorecherche Inhibitors of sex steroid biosynthesis and methods for their production and use
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5446203A (en) * 1992-08-25 1995-08-29 New York University Synthesis of haloenones and aryl or alkyl substituted enones or alkenes
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5354861A (en) * 1992-11-04 1994-10-11 National University Of Singapore 2-(benzyl)-3-arylbenzofurans as antitumour and hypocholesterolemic agents
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2162586C (en) * 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
ES2105525T3 (es) * 1993-06-24 1997-10-16 Lilly Co Eli 2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos.
GB9326255D0 (en) * 1993-12-23 1994-02-23 Roussel Lab Ltd Medical device for the prevention and treatment of cancer
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
UA41909C2 (uk) 1994-07-22 2001-10-15 Елі Ліллі Енд Компані Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
CA2223595C (en) 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
DE19526146A1 (de) * 1995-07-07 1997-01-09 Schering Ag Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
HUP9900951A3 (en) 1996-01-20 2000-02-28 Bradford University Bradford Process for producing tamoxifen and analogues thereof
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6083990A (en) * 1997-04-02 2000-07-04 Pharmos Corporation Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
CA2280181A1 (en) * 1997-02-09 1998-08-13 Pharmos Corporation Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
JP2001513105A (ja) * 1997-02-27 2001-08-28 フアルマシア・アンド・アツプジヨン・カンパニー 塩酸イリノテカン誘発性下痢軽減治療薬としてのタモキシフェン
GB9715479D0 (en) * 1997-07-23 1997-10-01 Univ Bradford Tamoxifen and analogues thereof
RU2214236C2 (ru) 1997-08-15 2003-10-20 Дьюк Юниверсити Способ профилактики или лечения эстрогензависимых заболеваний и расстройств
UA66370C2 (en) 1997-12-16 2004-05-17 Lilly Co Eli Arylpiperazines having activity to setotonin 1 receptors
GB9824207D0 (en) * 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
GB0012291D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
RU2188000C1 (ru) * 2001-09-27 2002-08-27 Нестерук Владимир Викторович Лекарственное средство на основе тамоксифена
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
AU2003254261B2 (en) * 2002-07-30 2008-04-17 Children's Medical Center Corporation Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
JP2007505881A (ja) * 2003-09-19 2007-03-15 ファイザー・プロダクツ・インク ２−アルキリデン−１９−ノル−ビタミンｄ誘導体およびエストロゲンアゴニスト／アンタゴニストの組合せを含む医薬組成物および方法
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
AU2005219441A1 (en) 2004-03-02 2005-09-15 Acceleron Pharma Inc. ALK7 and myostatin inhibitors and uses thereof
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
AU2006207325B2 (en) 2005-01-21 2012-08-16 Astex Therapeutics Limited Pharmaceutical compounds
KR20130028149A (ko) 2005-07-18 2013-03-18 바이파 사이언스 인코포레이티드 암의 치료
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
EP2029128B1 (en) 2006-05-22 2015-08-05 Hormos Medical Ltd. Method of treatment of chronic nonbacterial prostatitis with selective estrogen receptor modulators or aromatase inhibitors
BRPI0711525A2 (pt) 2006-06-02 2011-11-01 Pear Tree Women S Health Care composição farmacêutica e método para tratar sintomas de vaginite atrófica
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
ES2617957T3 (es) 2007-08-03 2017-06-20 Summit (Oxford) Limited Combinaciones farmacológicas para el tratamiento de la distrofia muscular de Duchenne
EA017385B1 (ru) 2007-10-16 2012-12-28 Репрос Терапьютикс Инк. Применение транс-кломифена для снижения концентрации глюкозы в сыворотке
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
JP2015505562A (ja) 2012-01-31 2015-02-23 ノバルティス アーゲー Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用
AU2013225869B2 (en) 2012-02-29 2017-06-08 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
CN104203961B (zh) 2012-03-05 2017-05-17 泽维尔大学 作为用于治疗乳腺癌的基于硼的4‑羟基他莫昔芬和因多昔芬前药
CN103992234B (zh) * 2014-06-11 2016-05-18 扬子江药业集团江苏海慈生物药业有限公司 一种枸橼酸他莫昔芬e异构体的制备方法
US11633382B2 (en) 2015-11-10 2023-04-25 Paracrine Therapeutics Ab Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen
EP3400009A2 (en) 2016-01-05 2018-11-14 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
WO2018027175A1 (en) 2016-08-04 2018-02-08 University Of Iowa Research Foundation Use of swell1 inhibitors and modulators to treat type 2 diabetes and obesity
WO2018034945A1 (en) 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
MX2020008680A (es) 2018-02-21 2020-09-25 Ai Therapeutics Inc Terapia de combinacion con apilimod y agentes glutamatergicos.
AU2020292279A1 (en) * 2019-06-10 2022-01-27 University Of Iowa Research Foundation Swell 1 modulators for treatment of non-alcoholic fatty liver disease, immune deficiencies, male infertility and vascular diseases
CN114133334B (zh) * 2021-11-09 2024-07-19 北京京丰制药(山东)有限公司 枸橼酸他莫昔芬的工业化制备工艺
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
EP4311546A1 (en) 2022-07-26 2024-01-31 Dynacure Combination therapy for myopathies
WO2024254189A1 (en) 2023-06-06 2024-12-12 Daré Bioscience, Inc. Compositions and methods for treating vulvar and vaginal atrophy (vva)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (cg-RX-API-DMAC7.html) * 1962-09-13
GB1013907A (en) * 1962-09-13 1965-12-22 Ici Ltd Alkene derivatives
GB1029221A (en) * 1963-09-02 1966-05-11 Ici Ltd Triarylalkane derivatives
US3288806A (en) * 1964-03-23 1966-11-29 Parke Davis & Co Alpha-(aminoethoxyphenyl)-alpha-alkylstilbenes
GB1099093A (en) * 1965-09-03 1968-01-17 Ici Ltd Alkene derivatives
GB1560274A (en) * 1977-02-28 1980-02-06 Ici Ltd Phenylbut 1-ene derivatives having antiostrogenicactivity

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2401132A1 (fr) * 1977-08-22 1979-03-23 Ici Ltd Nouveaux derives de triphenylbutene-1, leur procede de production et composition pharmaceutique les contenant
FR2463121A1 (fr) * 1979-08-15 1981-02-20 Egyt Gyogyszervegyeszeti Gyar Derives du 1,1,2-triphenylpropane et du 1,1,2-triphenylpropene, procede de preparation de ces derives et compositions pharmaceutiques contenant ces nouveaux composes
EP0659421A1 (en) * 1993-12-21 1995-06-28 Eli Lilly And Company 2-Phenyl-3-azoylbenzothiophenes for treating menstrual symptoms
EP0659420A1 (en) * 1993-12-21 1995-06-28 Eli Lilly And Company 2-Phenyl-3-azoylbenzothiophenes for treating sexual precocity
EP0659415A3 (en) * 1993-12-21 1995-10-11 Lilly Co Eli Inhibition of vasomotor symptoms and treatment of psychological complaints related to post-menopausal syndrome.
EP0659413A3 (en) * 1993-12-21 1995-10-11 Lilly Co Eli Inhibiting CNS problems in postmenopausal women.

Also Published As

Publication number Publication date
US4536516A (en) 1985-08-20
CH538447A (de) 1973-06-30
CH441286A (de) 1967-08-15
DE1568834A1 (de) 1970-11-26
DK117953B (da) 1970-06-22
CH446289A (de) 1967-11-15
BR6352734D0 (pt) 1973-09-18
DE1468088A1 (de) 1969-07-31
DK127777B (da) 1974-01-07
GB1064629A (en) 1967-04-05
DK118655B (da) 1970-09-21
FR1502607A (fr) 1967-11-24
BE637389A (cg-RX-API-DMAC7.html)
BR6678265D0 (pt) 1973-09-18

Similar Documents

Publication Publication Date Title
BE616548R (cg-RX-API-DMAC7.html)
BE678807A (cg-RX-API-DMAC7.html)
BE615521A (cg-RX-API-DMAC7.html)
BE613529A (cg-RX-API-DMAC7.html)
BE634722A (cg-RX-API-DMAC7.html)
BE634094A (cg-RX-API-DMAC7.html)
BE632989A (cg-RX-API-DMAC7.html)
BE631946A (cg-RX-API-DMAC7.html)
BE631809A (cg-RX-API-DMAC7.html)
BE631711A (cg-RX-API-DMAC7.html)
BE614159A (cg-RX-API-DMAC7.html)
BE631556A (cg-RX-API-DMAC7.html)
BE631226A (cg-RX-API-DMAC7.html)
BE629403A (cg-RX-API-DMAC7.html)
BE628241A (cg-RX-API-DMAC7.html)
BE628176A (cg-RX-API-DMAC7.html)
BE627763A (cg-RX-API-DMAC7.html)
BE613862A (cg-RX-API-DMAC7.html)
BE627381A (cg-RX-API-DMAC7.html)
BE626767A (cg-RX-API-DMAC7.html)
BE622397A (cg-RX-API-DMAC7.html)
BE621944A (cg-RX-API-DMAC7.html)
BE616785A (cg-RX-API-DMAC7.html)
BE616490A (cg-RX-API-DMAC7.html)
BE616386A (cg-RX-API-DMAC7.html)